CAS: 29110-47-2; N-Carbamimidoyl-2-(2,6-Dichlorophenyl)Acetamide

该化合物是一种主要用于治疗缺氧多动障碍(ADHD)和高血压的药物,被归类为甲型-2肾上腺激动剂,这意味着它通过刺激大脑中的甲型-2受体来起到作用,导致同情性外流减少和血压减少. guanfacine的化学配方是C9H9ClN2, 具有一种带有苯基环的guanidine结构,有助于其药理特性. Guanfacine通常在盐盐的盐状中施用,提高其溶性性和生物利用率. 该物质以其镇静剂作用著称,这可能有助于控制ADHD症状,特别是儿童. 常见的副作用可能包括沉睡,干口和疲劳. 由于其行动机制, guanfacine还会导致胸腔和低温,因此需要在治疗过程中进行仔细监测.

结构式图片

欧盟法规

ECHA物质C&L通报REACH预注册

上下游产品

CAS号6575-24-2 2,6-二氯苯基乙酸 | CAS号14527-26-5 S-甲基异硫脲硫酸盐 | CAS号3215-64-3 2,6-二氯苯乙腈 | CAS号54551-83-6 2,6-二氯苯基乙酸甲酯 | CAS号113-00-8 guanidine

合成工艺路线路线简述

    📜在 Ammonium Hydroxide体系中,化学反应 3.0H,反应生成胍法辛
    参考文献:盐酸胍法辛的制备方法
    标题:盐酸胍法辛的制备方法
    摘要:本发明公开了一种盐酸胍法辛的制备方法.以2,6‑二氯苯乙酸和甲氧基异脲盐酸盐为起始原料,经催化缩合,氨解,成盐,纯化制得盐酸胍法辛.该制备方法反应条件温和,操作简单,与现有技术相比,减少了操作步骤,降低了总反应时间,减少能耗,污染更小,有利于环保.

    海关参考信息

    专利信息


    专利号:US-10925977-B2
    优先权日:2006-10-05
    标 题 :Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
    发明人:YANG DAVID J; YU DONGFANG; THOMPSON ANDREW S
    权利人:YANG DAVID J; YU DONGFANG; THOMPSON ANDREW S; CEIL POINT LLC; UNIV TEXAS
    摘要:Novel methods of synthesis of chelator-targeting ligand conjugates, compositions comprising such conjugates, and therapeutic and diagnostic applications of such conjugates are disclosed. The compositions include chelator-targeting ligand conjugates optionally chelated to one or more metal ions. Methods of synthesizing these compositions in high purity are also presented. Also disclosed are methods of imaging, treating and diagnosing disease in a subject using these novel compositions, such as methods of imaging a tumor within a subject and methods of diagnosing myocardial ischemia.

    专利号:US-RE41998-E
    优先权日:1990-02-26
    标题 :Compositions and methods of treatment of sympathetically maintained pain
    发明人:CAMPBELL JAMES N
    权利人:ARCLON THERAPEUTICS INC
    摘要:Sympathetically maintained pain is treated topically by administering to the site where sympathetically maintained pain is present an α-1-adrenergic antagonist, α-2-adrenergic agonist, or other drug that depletes or blocks synthesis of sympathetic norepinephrine, known collectively as sympatholytic agents. Chemical formulas for several sympatholytic agents are given.

    专利号:US-9556123-B2
    优先权日:2004-07-19
    标题:Synthesis of triethylenetetramines
    发明人:JONAS MARCO; VAULONT IRENE; SOI ANTONIO; SCHMIDT GUNTHER
    权利人:PHILERA NEW ZEALAND LTD
    摘要:Methods and intermediates for synthesizing triethylenetetramine and salts thereof, as well as novel triethylenetetramine salts and their crystal structure, and triethylenetetramine salts of high purity.

    专利号:US-8487108-B2
    优先权日:2005-11-14
    标题 :Piperidinyl carbamate intermediates for the synthesis of aspartic protease inhibitors
    发明人:BALDWIN JOHN J; CLAREMON DAVID A; TICE COLIN; CACATIAN SALVACION; DILLARD LAWRENCE W; ISHCHENKO ALEXEY V; YUAN JING; XU ZHENRONG; MCGEEHAN GERARD; SIMPSON ROBERT D; SINGH SURESH B; ZHAO WEI; FLAHERTY PATRICK T
    权利人:BALDWIN JOHN J; CLAREMON DAVID A; TICE COLIN; CACATIAN SALVACION; DILLARD LAWRENCE W; ISHCHENKO ALEXEY V; YUAN JING; XU ZHENRONG; MCGEEHAN GERARD; SIMPSON ROBERT D; SINGH SURESH B; ZHAO WEI; FLAHERTY PATRICK T; VITAE PHARMACEUTICALS INC
    摘要:The present invention is directed to aspartic protease inhibitors. Certain aspartic protease inhibitors of the invention can be represented by the following structural formula or a pharmaceutically acceptable salt thereof. The present invention is also directed to pharmaceutical compositions comprising the disclosed aspartic protease inhibitors. The present invention is further directed to methods of antagonizing one or more aspartic proteases in a subject in need thereof, and methods for treating an aspartic protease mediated disorder in a subject using the disclosed aspartic protease inhibitors.

    专利号:US-2020148647-A1
    优先权日:2004-07-19
    标题:Synthesis of Triethylenetetramines

    专利号:US-2008039473-A1
    优先权日:2006-08-08
    标题:Preparation and utility of substituted quinazoline compounds with alpha-adrenergic blocking effects
    发明人:GANT THOMAS G; SARSHAR SEPEHR
    权利人:AUSPEX PHARMACEUTICALS INC
    摘要:The present disclosure is directed to modulators of alpha-adrenergic receptors and pharmaceutically acceptable salts and prodrugs thereof, the chemical synthesis thereof, and the use of such compounds for the treatment and/or management of hypertension, cardiac failure, prostatitis, and benign prostatic hyperplasia, and any other condition in which it is beneficial to modulate an alpha-adrenergic receptor.

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献

    1. Huss M, Chen W, Ludolph AG. Guanfacine Extended Release: A New Pharmacological Treatment Option in Europe. Clin Drug Investig. 2016 Jan;36(1):1-25. doi: 10.1007/s40261-015-0336-0.

    合成参考文献


    参考文献:10.1016/j.ijpsycho.2011.06.022
    摘要:McAllister TW, McDonald BC, Flashman LA, Ferrell RB, Tosteson TD, Yanofsky NN, Grove MR, Saykin AJ. Alpha-2 adrenergic challenge with guanfacine one month after mild traumatic brain injury: Altered working memory and BOLD response. International Journal of Psychophysiology. 2011 Oct;82(1):107–14. doi: 10.1016/j.ijpsycho.2011.06.022.
    参考文献:10.1007/s00213-011-2405-2
    摘要:Pattij T, Schetters D, Schoffelmeer AN, van Gaalen MM. On the improvement of inhibitory response control and visuospatial attention by indirect and direct adrenoceptor agonists. Psychopharmacology (Berl). 2012 Jan;219(2):327–40.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知